Company Overview and News
Electric vehicles have a long road ahead of them, even if Tesla sees a few twists and turns along the way.
PILBF SSNLF CCZ RNSDF HAV GALXF ALTAF GM.WS.A GM.WS.B GM.WS.C GM VLKAY PLS AYR BC94 SMSN BSWQY DDAIF TWNAF KATFF GXY KAT TAW GOOGL MU GM.WSB AJM SMSD
Markets are taking a chance to settle down after a rocky week last week. Sentiment continues to be cautious. These are some of the small and mid-cap stories from Wednesday on the JSE:
KIBO TAW TWNAF
Lithium spot and contract price news - Spot prices very slightly down and contract prices rising.
LIT BCN PILBF LTHHF SAV LAXXF LIACF AGY NMT 40F PLLLY RDRUY AZZVF WML SQM MLNLF AIS.H KDR SYA STLHF WMLLF LNRDY NGZ AMVMF VLKAF LMMFF GXY TAW LRS MNIKF ILHMF AMLM ALB DMNXF MALRY BGS LACDF EEYMF MIN NMKEF ARYMF ILC MGXMF LSSCF ALTAF DJIFF NMX EMH PSC CRECF OROCF ERPNF LAC PLS FTI.WI FMC BCN TWNAF DJI RRSSF PDDTF NTTHF AVLIF NTR MALRF ORE AVZ AJM BCRMF
Australia’s lithium sector was tipped to see a surge in mergers and acquisitions (M&A) and operational development this year — and so far it hasn’t disappointed.
PLS KDR PILBF MALRY TWNAF MIN 40F GXY GALXF TAW ALTAF MALRF AJM
Tawana Resources NL (TAW:ASX) and Alliance Mineral Assets (SGX:40F) have shipped the first batch of spodumene (lithium) concentrate from the Bald Hill lithium and tantalum mine.
40F TAW TWNAF
Lithium spot and contract price news - China spot prices slightly down, global contract prices remain firm.
LIT BCN PILBF LTHHF SAV LAXXF MS.PRE MS.PRF LIACF MS.PRG AGY MS.PRA NMT 40F PLLLY RDRUY AZZVF MS WML SQM MLNLF AIS.H KDR SYA STLHF WMLLF LNRDY NGZ LMMFF GXY MS.PRI TAW LRS MNIKF MS.PRK ILHMF AMLM ALB DMNXF MALRY BGS LACDF EEYMF MIN TKL NMKEF ARYMF ILC MGXMF LSSCF ALTAF DJIFF NMX EMH PSC CRECF OROCF ERPNF LAC PLS FTI.WI FMC BCN TWNAF DJI RRSSF PDDTF NTTHF AVLIF MALRF ORE AVZ AJM BCRMF
Bald Hill lithium mine joint venture partners Tawana Resources and Alliance Mineral Assets are planning a merger to consolidate ownership of the Western Australian operation.
40F SPXCY TAW SPXCF EGS EGDD TWNAF ESGFF S68
Tawana Resources and joint venture partner Alliance Mineral Assets have completed the first of three performance tests at the Bald Hill lithium plant in the Eastern Goldfields region of Western Australia, returning high-quality concentrate results in excess of 6 per cent lithium oxide.
40F TAW EGS EGDD TWNAF ESGFF
Lithium spot and contract price news - Lithium spot prices were stable, while 2018 LCE global contract prices are about 20% higher than 2017.
LIT ORL BCN PILBF LTHHF LAXXF MS.PRE MS.PRF LIACF MS.PRG AGY MS.PRA NMT AGO GM.WS.A GM.WS.B GM.WS.C PLLLY RDRUY AZZVF MS WML SQM MLNLF AIS.H KDR STLHF SYA AGODY WMLLF LNRDY LIXXF NGZ AMVMF VLKAF GXY LMMFF MS.PRI TAW LRS MNIKF MS.PRK ILHMF AMLM 8015 GM.WSB ALB DMNXF TYHOF MALRY BGS LACDF EEYMF KIMTY MIN NMKEF TKL ARYMF ILC LIX MGXMF LSSCF ALTAF DJIFF KIMTF NMX CRECF EMH PSC GM OROCF ERPNF LAC PLS HYUO BCN TWNAF QBC HYUD DJI RRSSF SSDIY PDDTF NTTHF AVLIF ATLGF HYUP MALRF ORE AVZ AJM BCRMF
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to ASX:TAW / TAWANA RESOURCES NL on message board site Silicon Investor.